Please assess the completion status of the following clinical trial:

Trial Title: Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Scheduled for an ERCP at Dartmouth-Hitchcock~2. Age greater than 18 years old~3. Ability to provide written informed consent~Exclusion Criteria:~1. Inability to provide written informed consent~2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis~3. Current ongoing acute pancreatitis~4. Previously documented allergy to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)~5. Contra-indication to NSAID therapy (creatinine level \>1.4 or active peptic ulcer disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)~6. Pregnant or nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: EXPERIMENTAL): Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo suppositories (#2)

Based on this trial design, predict the completion outcome and termination type (if applicable).